72.74
3
[]. Adams KN, et al. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis. 204 Aug ;20(3):45-.
[2]. Choi DH, et al. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34(3-4):3-8.
[3]. Pauli-Magnus C, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):37-82.
[4]. Wang J et al. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 203 Nov 20;50(3-4):290-302.
[5]. Amy C Young, et al. Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. Resuscitation. 2009 May;80(5):59-3.
H302-H35-H39-H335
P2-P24-P270-P27-P280-P302+P352-P304+P340-P330-P32+P34-P405-P50
GHS0,GHS08
.
28